Reviewmoderate evidence
Androgen Society Position Paper on Cardiovascular Risk With Testosterone Therapy.
Mayo Clinic proceedings·November 1, 2024·PMID 39436329
Why it mattersClinicians managing testosterone deficiency in men with or at risk for cardiovascular disease need clear guidance on the cardiovascular safety of testosterone therapy. This position paper synthesizes the TRAVERSE trial and existing evidence to support that TTh does not increase major adverse cardiovascular events, helping to inform treatment decisions and patient counseling.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled